# EDGAR Filing Document

**Accession Number:** 0001589150
**File Stem:** 0001641172-25-023226
**Filing Date:** 2025-8
**Character Count:** 2389
**Document Hash:** a038cf0c7eeb1ab8f085ef9aef3079b5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-023226.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0001641172-25-023226

**CONFORMED SUBMISSION TYPE**: 1-A-W

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250812

**DATE AS OF CHANGE**: 20250812

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Regen BioPharma Inc
- **CENTRAL INDEX KEY:** 0001589150
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 455192997
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 1-A-W
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-12505
- **FILM NUMBER:** 251207580

**BUSINESS ADDRESS:**
- **STREET 1:** 4700 SPRING ST #304
- **CITY:** LA MESA
- **STATE:** CA
- **ZIP:** 91942
- **BUSINESS PHONE:** 619-722-5505

**MAIL ADDRESS:**
- **STREET 1:** 4700 SPRING ST #304
- **CITY:** LA MESA
- **STATE:** CA
- **ZIP:** 91942

August 12, 2025

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Regen Biopharma, Inc.

Withdrawal of Offering Statement on Form 1-A

File No. 024-12505

Ladies and Gentlemen:

Pursuant to Rule 259(a) under Regulation A of the Securities Act of 1933, as amended, Regen Biopharma, Inc. (the "Company") hereby respectfully requests the withdrawal of the above-referenced Offering Statement, together with all amendments and exhibits thereto (collectively, the "Offering Statement"), originally filed with the Securities and Exchange Commission (the "Commission") on September 16, 2024 and qualified by the Commission on December 10, 2024.

The Company confirms none of the securities that are the subject of the Offering Statement have been sold and the Company has determined not to proceed with this offering. Accordingly, the Company respectfully requests that the Commission issue an order granting the withdrawal of the Offering Statement effective as of the date hereof or at the earliest practicable date hereafter.

Should you have any questions regarding these matters, please contact David Koos, Chairman and CEO of the Company at 619 227 9192

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| Regen Biopharma, Inc. | Regen Biopharma, Inc. |
| By: | */s/ David Koos* |
| Name: | Davis Koos |
| Title: | Chairman, Chief Executive Officer and President |

---